How to define a cut-off value of tumour markers in haemodialysis patients?
作者信息
Mercadal Lucile, Cormont Sylvie, Tezenas-du-Montcel Sophie, Hacini Sabria, Venditto Marcia, Deray Gilbert
机构信息
Nephrology Department.
Biology Department , Pitié Salpétrière Hospital , 83 bd de l'hopital, 75013 Paris , France E-mail:
出版信息
NDT Plus. 2009 Apr;2(2):188-9. doi: 10.1093/ndtplus/sfn216.
Abstract
摘要
相似文献
1
How to define a cut-off value of tumour markers in haemodialysis patients?如何定义血液透析患者肿瘤标志物的临界值？
NDT Plus. 2009 Apr;2(2):188-9. doi: 10.1093/ndtplus/sfn216.
2
High cut-off dialysis in chronic haemodialysis patients.高通量透析在慢性血液透析患者中的应用。
Eur J Clin Invest. 2015 Dec;45(12):1333-40. doi: 10.1111/eci.12559.
3
The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin.铁状态标志物在预测维持性促红细胞生成素治疗的血液透析患者对静脉铁剂反应中的作用
Nephrol Dial Transplant. 2001 Jul;16(7):1416-23. doi: 10.1093/ndt/16.7.1416.
4
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.采用肿瘤标志物对乳腺癌患者进行强化术后随访：癌胚抗原（CEA）、组织多肽抗原（TPA）或糖类抗原15.3（CA15.3）与巨嗜细胞趋化蛋白（MCA）对比，以及MCA - CA15.3与CEA - TPA - CA15.3组合在远处转移早期检测中的应用
BMC Cancer. 2006 Nov 20;6:269. doi: 10.1186/1471-2407-6-269.
5
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.2008 - 2012年奥克兰地区采用高通量血液透析治疗骨髓瘤管型肾病
Nephrology (Carlton). 2014 Jul;19(7):432-5. doi: 10.1111/nep.12267.
6
Decision guarantee in tumour marker analysis: a cut-off independent assessment.肿瘤标志物分析中的决策保证：一种与临界值无关的评估
Anticancer Res. 2007 Jul-Aug;27(4A):1933-9.
7
8
Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.高截留率血液透析滤过治疗多发性骨髓瘤相关Cast 肾病：我们的经验。
Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932.
9
Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients.REMOVAL-HD研究的设计与方法：一项评估血液透析患者中白蛋白和轻链中间截断值膜清除率的试验
BMC Nephrol. 2018 Apr 17;19(1):89. doi: 10.1186/s12882-018-0883-8.
10
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer.选择结直肠癌进展和生存新生物标志物的免疫组化临界值。
J Clin Pathol. 2007 Oct;60(10):1112-6. doi: 10.1136/jcp.2006.044537. Epub 2006 Dec 20.
本文引用的文献
1
Tumor markers in hemodialysis patients.血液透析患者的肿瘤标志物
Transplant Proc. 1999 Dec;31(8):3367-8. doi: 10.1016/s0041-1345(99)00846-5.
2
Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
Oncol Rep. 1998 Mar-Apr;5(2):389-92. doi: 10.3892/or.5.2.389.
3
Serum tumour markers in renal failure.
Int Urol Nephrol. 1996;28(4):601-4. doi: 10.1007/BF02550974.
4
Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.慢性血液透析患者的获得性肾囊肿疾病与肿瘤标志物
Int J Artif Organs. 1997 Feb;20(2):96-100.
5
The effect of renal function on serum levels of CA 125.
Gynecol Oncol. 1995 Sep;58(3):375-7. doi: 10.1006/gyno.1995.1245.
6
Tumour markers in chronic renal failure and haemodialysis patients.慢性肾衰竭及血液透析患者的肿瘤标志物
Nephrol Dial Transplant. 1995;10(7):1256.
7
Elevated tumor markers in hemodialysis patients.
Am J Nephrol. 1988;8(3):187-9. doi: 10.1159/000167580.
8
Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.血液透析对尿毒症患者癌胚抗原、甲胎蛋白、鳞状细胞癌相关抗原、神经元特异性烯醇化酶、CA 125、CA 19-9和CA 15-3这七种肿瘤标志物浓度的影响。
Am J Nephrol. 1991;11(5):363-8. doi: 10.1159/000168339.
9
Tumor markers in patients undergoing hemodialysis or kidney transplantation.接受血液透析或肾移植患者的肿瘤标志物
Nephron. 1991;59(4):618-20. doi: 10.1159/000186653.
10
Tumor markers in patients with chronic renal failure.慢性肾衰竭患者的肿瘤标志物
Int J Biol Markers. 1990 Apr-Jun;5(2):85-8.
Zotero 插件